These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21477928)

  • 41. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
    Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
    Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
    Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
    J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique.
    Parkinson B; Pearson SA; Viney R
    Eur J Health Econ; 2014 Jan; 15(1):93-112. PubMed ID: 23436142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Financial Costs and Burden Related to Decisions for Breast Cancer Surgery.
    Greenup RA; Rushing C; Fish L; Campbell BM; Tolnitch L; Hyslop T; Peppercorn J; Wheeler SB; Zafar SY; Myers ER; Hwang ES
    J Oncol Pract; 2019 Aug; 15(8):e666-e676. PubMed ID: 31356147
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patient recommendations for reducing long-lasting economic burden after breast cancer.
    Dean LT; Moss SL; Rollinson SI; Frasso Jaramillo L; Paxton RJ; Owczarzak JT
    Cancer; 2019 Jun; 125(11):1929-1940. PubMed ID: 30839106
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
    Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
    Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation between Supportive Care Needs of Women with Breast Cancer and Quality of Life of their Family Caregivers.
    Mohammadzadeh Nimekari M; Saei Ghare Naz M; Ashouri Taziani Y; Nasiri M; Evazi MR; Shafizad A; Ozgoli G
    Int J Community Based Nurs Midwifery; 2019 Oct; 7(4):300-308. PubMed ID: 31641679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer.
    Hsu T; Nathwani N; Loscalzo M; Chung V; Chao J; Karanes C; Koczywas M; Forman S; Lim D; Siddiqi T; Stein A; Twardowski P; Nademanee A; Pal S; Siccion E; Hein M; Akiba C; Goldstein L; Smith D; Ma H; Feng T; Hurria A
    J Am Geriatr Soc; 2019 May; 67(5):978-986. PubMed ID: 30901083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of a psychosocial intervention on the quality of life of primary caregivers of women with breast cancer.
    Gabriel IO; Mayers PM
    Eur J Oncol Nurs; 2019 Feb; 38():85-91. PubMed ID: 30717942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world patient- and caregiver-reported outcomes in advanced breast cancer.
    Lambert-Obry V; Gouault-Laliberté A; Castonguay A; Zanotti G; Tran T; Mates M; Lemieux J; Chabot P; Prady C; Couture F; Lachaine J
    Curr Oncol; 2018 Aug; 25(4):e282-e290. PubMed ID: 30111973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Experiencing an Intimate Partner's Breast Cancer: Attachment, Caregiving, and Burden in Men.
    Ávila M; Brandão T; Coimbra JL; Lopez F; Matos PM
    Psychiatry; 2016; 79(3):236-248. PubMed ID: 27880619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transitions of male partners of women with breast cancer: hope, guilt, and quality of life.
    Duggleby W; Thomas J; Montford K; Thomas R; Nekolaichuk C; Ghosh S; Cumming C; Tonkin K
    Oncol Nurs Forum; 2015 Mar; 42(2):134-41. PubMed ID: 25806880
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality of life and depression in caregivers of patients with breast cancer.
    Heidari Gorji MA; Bouzar Z; Haghshenas M; Kasaeeyan AA; Sadeghi MR; Ardebil MD
    BMC Res Notes; 2012 Jun; 5():310. PubMed ID: 22715918
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quality of life and coping of women treated for breast cancer and their caregiver. What are the interactions?
    Bonnaud-Antignac A; Hardouin JB; Leger J; Dravet F; Sebille V
    J Clin Psychol Med Settings; 2012 Sep; 19(3):320-8. PubMed ID: 22669411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
    Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
    Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
    Li JB; Lin ZC; Wong MCS; Wang HHX; Li M; Li S
    BMC Med; 2022 Sep; 20(1):320. PubMed ID: 36156186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.
    Haidari RE; Anota A; Dabakuyo-Yonli TS; Guillemin F; Conroy T; Velten M; Jolly D; Causeret S; Cuisenier J; Graesslin O; Abbas LA; Nerich V
    Qual Life Res; 2022 Oct; 31(10):3077-3085. PubMed ID: 35590124
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review.
    Huang M; Haiderali A; Fox GE; Frederickson A; Cortes J; Fasching PA; O'Shaughnessy J
    Pharmacoeconomics; 2022 May; 40(5):519-558. PubMed ID: 35112331
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT.
    Naghavi-Behzad M; Vogsen M; Vester RM; Olsen MMB; Oltmann H; Braad PE; Asmussen JT; Gerke O; Vach W; Kidholm K; Kodahl AR; Weber W; Hildebrandt MG
    Br J Cancer; 2022 May; 126(9):1271-1279. PubMed ID: 35013575
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands.
    Schneider PP; Ramaekers BL; Pouwels X; Geurts S; Ibragimova K; de Boer M; Vriens B; van de Wouw Y; den Boer M; Pepels M; Tjan-Heijnen V; Joore M
    Value Health; 2021 May; 24(5):668-675. PubMed ID: 33933235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.